Regeneron Pharmaceuticals Inc
REGN.O- Latest Trade
- trading higher661.14USD
- Change
- 3.99
- % Change
0.61%Positive
- Day Range
- 647.54 - 664.90
- 52-Week Range
- 492.13 - 747.42
As of May 21 2022. Values delayed up to 15 minutes
- Previous Close
- 657.15
- Open
- 661.29
- Volume
- 544,265.00
- 3 Month Average Trading Volume
- 13.64
- Shares Out (Mil)
- 109.85
- Market Cap
- 72,623.71
- Forward P/E
- 14.95
- Dividend Yield
- -99,999.99
Key Statistics
2.29166667 mean rating - 24 analysts
- P/E Excl. Extra Items (TTM)
- 9.37
- Price To Sales (TTM)
- 4.40
- Price To Book (Quarterly)
- 3.64
- Price To Cash Flow (Per Share TTM)
- 8.83
- Total Debt/Total Equity (Quarterly)
- 13.56
- Long Term Debt/Equity (Quarterly)
- 13.56
- Return On Investment (TTM)
- 41.87
- Return On Equity (TTM)
- 35.96
2021 (millions USD)
About Regeneron Pharmaceuticals Inc
Company Information
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. Its product candidates in clinical development include REGN4018, REGN5668, and Fasinumab, among others.
Address
777 Old Saw Mill River RdTARRYTOWN, NY
10591-6717
United States
Industry
Biotechnology & Drugs
Executive Leadership
- P. Roy Vagelos
- Chairman of the Board
- Leonard S. Schleifer
- President, Chief Executive Officer, Founder, Director
- George D. Yancopoulos
- President, Chief Scientific Officer, Director
- Robert E. Landry
- Chief Financial Officer, Executive Vice President - Finance
- Joseph J. LaRosa
- Executive Vice President, General Counsel, Secretary
- Daniel P. Van Plew
- Executive Vice President, General Manager - Industrial Operations and Product Supply
- Marion E. McCourt
- Executive Vice President - Commercial
- Andrew J. Murphy
- Executive Vice President - Research
- Neil Stahl
- Executive Vice President - Research and Development
- Christopher R. Fenimore
- Senior Vice President, Controller
- Bonnie L. Bassler
- Independent Director
- Michael S. Brown
- Independent Director
- N. Anthony Coles
- Independent Director
- Joseph L. Goldstein
- Independent Director
- Christine A. Poon
- Independent Director
- Arthur F. Ryan
- Independent Director
- George L. Sing
- Independent Director
- Marc Tessier-Lavigne
- Independent Director
- Huda Y. Zoghbi
- Independent Director
Latest News
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,836.30 | 0.27%Negative |
| Copper | 772.55 | 0.46%Positive |
| Brent Crude Oil | 112.55 | -- |
| CBOT Soybeans | 1,705.75 | 0.90%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,901.36 | 0.01%Positive |
| Euro STOXX 50 | 3,657.03 | 0.45%Positive |
| FTSE 100 | 7,389.98 | 1.19%Positive |
| Nikkei 225 | 26,739.03 | 1.27%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes